Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice

Abstract

1 The International Conference on the Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for human use (ICH) has agreed that bioassay data from only one species, the rat, supported by appropriate mutagenicity and pharmacokinetic data and also information from new (unvalidated) short term in vivo screening tests for potential carcinogenicity, could be used for the licensing of human medicines. This proposal has been supported by reviews of the utility of testing pharmaceuticals in the mouse which have concluded that the mouse bioassay contributes little to regulatory decisions. The current review was undertaken to identify `genuine' mouse-specific carcinogens using the Gold Carcinogenicity Potency Database (CPD) for the initial identification of potential mouse-specific carcinogens from published literature. Hazard assessments were completed for these chemicals with particular attention focused on the `genuine' mouse-specific carcinogens. The significance of such chemicals has been discussed together with consideration of on-going work on the validation of short-term carcinogenicity bioas-says using transgenic mice.

2 Seventy-six potential mouse specific carcinogens were identified through the Gold Carcinogenicity Potency Database. Following more detailed consideration a total of ten chemicals were excluded from further consideration (three were multispecies carcinogens, five were considered to be non-carcinogenic in the mouse, and the data for two were uninterpretable). The review focused on the remaining 66 chemicals. There was equivocal evidence of carcinogenicity to the rat for 28 chemicals and inadequate data for a further 23 chemicals. Fifteen `genuine' mouse-specific carcinogens were identified. These 15 chemicals comprise two genotoxic mouse-specific carcinogens (N-methylolacrylamide (924-42-5), 2,6-Dichloro-p-phenylenedia-mine (609-20-1); five non-genotoxic mouse-specific carcinogens 2-Aminobiphenyl.HCl (2185-92-4), Captan (133-06-2), Dieldrin (60-57-7), Diethylhexyladipate (103-23-1), and Probenicid (57-66-9); five mouse-specific carcinogens with equivocal evidence of mutagenicity were identified; (2,4-diaminophenol.2HCl (137-09-7), Dipyrone (68-89-3), Ozone (10028-15-6), Vinylidene chloride (75-35-4), and Zearalenone (17924-92-4)), and three mouse-specific carcinogens with inadequate mutagenicity data (Benzaldehyde (100-52-7), Piperonyl sulphoxide (120-62-7), Ripazepam (26308-28-1)).

3 It is suggested that the two genotoxic mouse carcinogens would have been considered as potential carcinogens in the absence of a mouse bioassay. Of the five non-genotoxic mouse-specific carcinogens; three induced tumours in mouse liver only and are considered as being of low potential hazard to human health. The remaining two chemicals would have been missed in the absence of a mouse bioassay (2-aminobiphenyl (2185-92-4) and captan (133-06-2)) and thus are good candidates for evaluation in the short term bioassays in transgenic mice currently being validated.

4 The hardest group of mouse-specific carcinogens to evaluate are those for which there is equivocal or inadequate mutagenicity data. The difficulty in evaluating these particular chemicals emphasises the need for adequate mutagenicity data in addition to adequate carcinogenicity data in order to assess potential hazards to human health. Hazard assessments and a consideration of the potential role for short-term bioassays in transgenic mice for the eight chemicals in this subgroup are presented.

5 A number of general conclusions have been derived from this review. Firstly, there are insufficient published genotoxicity data to allow a full assessment of mutagenic potential for 57/76 of the potential mouse-specific carcinogens identified from the CPD. This is surprising given the clear value of such data in interpreting bioassay results and the much greater resources required for carcinogenicity bioassays. Second, the newly proposed short-term tests in transgenic mice must be able to identify genotoxic carcinogens and this must include the very few mouse-specific genotoxic carcinogens. Third, there are relatively few non-genotoxic `genuine' mouse-specific carcinogens identifiable from the CPD, which may pose a significant human health hazard.

6 It is suggested that regulatory and industry data files for chemicals other than pharmaceuticals could be reviewed in order to ascertain the full significance of mouse only carcinogens.

Keywords

mouse carcinogen mutagen transgenic

Get full access to this article

View all access options for this article.

References

Fung VA , Huff J , Weisburger EK , Hoel DG. Predictive strategies for selecting 379 NCI/NTP chemicals evaluated for carcinogenic potential and public health impact . Fundamental and Applied Toxicology 1993; 20: 413-436 .

Van Oosterhout JPJ et al. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in europe . Regulatory Toxicology and Pharmacology 1997; 25: 6-17 .

ICH. International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for human use (ICH). Harmonised Tripartite Guideline . Testing for Carcinogenicity of Pharmaceuticals 1997.

Conterera JF , Jacobs AC , Degeorge JJ. Carcinogenicity testing and evaluation of Regulatory Requirements for Pharmaceuticals . Regulatory Toxicology and Pharmacology 1997; 25: 130-145 .

Alden CL , Smith PF , Piper CE , Brej L. A critical appraisal of the value of the mouse cancer bioassay in safety assessment . Toxicologic Pathology 1996; 24: 722-725 .

Maronpot RR , Boorman GA. The contribution of the mouse in Hazard identification studies . Toxicologic Pathology 1997; 24: 726-733 .

Gold LS et al. A carcinogenic potency database of the standardised results of animal bioassays . Environmental Health Perspectives 1984; 58: 9-323 .

Gold LS et al. Chronological supplement to the carcinogenic potency database: Standardised results of animal bioassays published through December 1982 . Environmental Health Perspectives 1986; 67: 161-200 .

Gold LS et al. Second chronological supplement to the carcinogenic potency database: Standardised results of animal bioassays published through December 1984 and by the National Toxicology Program through May 1986 . Environmental Health Perspectives 1987; 74: 237-329 .

10.

Gold LS et al. Third chronological supplement to the carcinogenic potency database: Standardised results through December 1986 and by the National Toxicology Program through June 1987 . Environmental Health Perspectives 1990; 84: 215-285 .

11.

Gold LS et al. The fifth plot of the carcinogenic potency database: Results of animal bioassays published in the general literature through 1988 and by the National Toxicology Program through 1989 . Environmental Health Perspectives 1993; 100: 65-135 .

12.

Gold LS et al. Sixth plot of the Carcinogenic Potency Database: Results of animal bioassays published in the general literature 1989 to 1990 and by the National Toxicology Program 1990-1993 . Environmental Health Perspectives 1995; 103(Suppl 7): 1-122 .

13.

Gold LS , Zeiger E. Handbook of Carcinogenic potency and genotoxicity databases. CRC Press Inc, New York , 1997.

14.

Gold LS , Berstein L , Magaw R and Slone TH. Interspecies extrapolation in carcinogenesis: Prediction between rats and mice . Environmental Health Perspectives 1989; 81: 211-219 .

15.

Ashby J , Tennant RW. Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by US NCI/NTP . Mutation Research 1988; 204: 17-115 .

16.

Ashby J , Paton D. The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures . Mutation Research 1993; 286: 3-74 .

17.

Haworth S et al. Salmonella mutagenicity results for 250 chemicals . Environmental and Molecular Mutagenesis 1983; 5(suppl 1): 3-142 .

18.

Mortlemans K et al. Salmonella mutagenicity tests II. Results from testing of 225 chemicals . Environmental and Molecular Mutagenesis 1986; 8(Suppl 7): 1-119 .

19.

Zeiger E et al. Salmonella mutagenicity tests IV. Results from testing of 300 chemicals . Environmental and Molecular Mutagenesis 1988; 11(Suppl 12): 1-157 .

20.

Zeigler E et al. Salmonella mutagenicity tests V. Results from testing of 311 chemicals . Environmental and Molecular Mutagenesis 1992; 19(Suppl 21): 2-141 .

21.

Zeiger E et al. Salmonella mutagenicity tests III. Results from testing of 255 chemicals . Environmental and Molecular Mutagenesis 1987; 9(Suppl 9): 1-110 .

22.

Dunkel VC et al. Reproducibility of microbial mutagenicity assays II. Testing of carcinogens and non-carcinogens in Salmonella typhimurium and Escherichia coli . Environmental and Molecular Mutagenesis 1985; 7(Suppl 5): 1-248 .

23.

24.

Galloway SM et al. Chromosome aberrations and Sister Chromatid Exchanges in Chinese Hamster Ovary cells. Evaluations of 108 chemicals . Environmental and Molecular Mutagenesis 1987; 10(Suppl 110) 1-175 .

25.

Caspary WJ et al. The mutagenic activity of selected chemicals at the TK locus: rodent versus human cells . Mutation Research 1988; 196: 61-81 .

26.

Myhr BC , Capary WJ. Evaluation of the LY5178Y mouse lymphoma cell mutagenesis assay. Interlaboratory results for 63 coded chemicals tested at Litton Bionetics Inc . Environmental and Molecular Mutagenesis 1988; 12(Suppl 113): 103-194 .

27.

McGregor DB. Response of the LY5178Y tk+/tk7mouse lymphoma cell mutation assay: Results from 72 coded chemicals . Environmental and Molecular Mutagenesis 1988; 12: 85-104 .

28.

Caspary WJ et al. Evaluation of the LY5178Y mouse lymphoma assay. Interlaboratory reproducibility and assessment . Environmental and Molecular Mutagenesis 1988; 12(suppl 13): 195-229 .

29.

Shelby MD , Erexso GL , Hook GJ , Tice RR. Evaluation of three exposure mouse bone marrow micronucleus protocol: Results with 49 chemicals . Environmental and Molecular Mutagenesis 1993; 21: 160-179 .

30.

Mvournin KH et al. The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the US Environmental Protection Agency Gene-Tox program . Mutation Research 1990; 239: 29-80 .

31.

Department of Health . 1995 Annual report of the Committees on Toxicity, Carcinogenicity and Mutagenicity of Chemicals in Food Consumer Products and the Environment. London HMSO , 1996.

32.

Piegorsch WW , Carr GJ , Portier CJ and Hoel DG. Concordance of carcinogenic response between rodent species: Potency dependence and potential underestimation . Risk Analysis 1992; 12: 115-121 .

33.

Freedman DA , Gold LS , Lin TH. Concordance between rats and mice in bioassays for carcinogenesis . Regulatory Toxicology and Pharmacology 1996; 23: 225-232 .

34.

World Health Organisation . International Agency for Research on Cancer. Cancer: Causes, Occurrence and Control . IARC Scientific Publications No 100, Lyon , 1990.

35.

Department of Health . 1996 Annual report of the Committees on Toxicity, Carcinogenicity and Mutagenicity of Chemicals in Food Consumer Products and the Environment. London HMSO , 1998.

36.

Brock N , Schneider, Stekar J , Pohl J. Experimental investigations into carcinogenic effect of antitumour and immunosuppressive agents . Journal of Cancer research and Clinical Oncology 1989; 115: 309-328 .

37.

Tennant RW , Ashby J. Classification according to chemical structure, mutagenicity to Salmonella and level of carcinogenicity of a further 39 chemicals tested for carcinogenicity by the US NTP . Mutation Research 1991; 257: 209-225 .

38.

National Toxicology Programme . Toxicology and carcinogenesis studies on N-methylolacrylamide in F344/N rats and B6C3F1 mice. NTP Technical report No 352. US DHSS, NIH 1989.

39.

Sakamoto J , Hashimoto K. Reproductive toxicity of acrylamide and related compounds in mice. Effects on fertility and sperm morphology . Archives of Toxicology 1986; 59: 207-215 .

40.

Shelby MD , Witt KL. Comparison of results from mouse bone marrow chromosome aberration and micronucleus test . Environmental and Molecular Mutagenesis 1995; 25: 302-313 .

41.

National Toxicology Programme . Carcinogenesis bioassay of 2,6-dichloro-p-diphenylenediamine (CAS 609-20-1) in F344/N rats and B6C3F1 mice. NTP Technical report No 219. US DHSS, NIH 1982.

42.

Tennant RW , French JE , Spalding JW. Identifying chemical carcinogens and assessing potential risks in short term bioassays and transgenic mouse models . Environmental Health Perspectives 1995; 103: 942-945 .

43.

World Health Organisation . IARC Monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: An updating of IARC Monographs volumes 1-42, supplement 7, Lyon, France , 1987.

44.

National Toxicology Programme . Carcinogenesis bioassay of 2-biphenylamine hydrochloride (CAS 2185-92-4) in F344/N rats and B6C3F1 mice. NTP Technical report No 81-35. US DHSS, NIH 1982.

45.

Department of Health 1993 Annual report of the Committees on Toxicity, Carcinogenicity and Mutagenicity of Chemicals in Food Consumer Products and the Environment. London, HMSO , 1994.

46.

National Toxicology Programme . Toxicology and Carcinogenesis studies of 2,4-diaminophenol. dihydrochloride (CAS 137-09-7) in F344 rats and B6C3F1 mice (gavage studies). NTP Technical report No TR 401. US DHSS, NIH 1992.

47.

National Toxicology Programme . Toxicology and Carcinogenesis studies of Ozone (CAS 10028-15-6) and Ozone/NNK (CAS No 10028-15-6/64091-91-4) in F344/N rats and B6C3F1 mice (inhalation studies). NTP Technical report No TR 440. US DHSS, NIH 1994.

48.

Maltoni C. Recent findings on the carcinogenicity of chlorinated olefins . Environmental Health Perspectives 1977; 21: 1-5 .

49.

Cotti G , Maltini C , Lefemine G. Long term carcinogenicity bioassay on vinylidene chloride administered by inhalation to Sprague-Dawley rats . Annals of the New York Academy of Sciences 1988; 534: 160-168 .

50.

Oesch F et al. Vinylidene chloride: changes in drug metabolising enzymes, mutagenicity and relation to its targets for carcinogenesis . Carcinogenesis 1983; 4: 1031-1038 .

51.

Speerschneider P , Dekant W. Renal tumourigenicity of 1,1-dichloroethene in mice: The role of male-specific expression of cytochrome P450 2E1 in the renal bioactivation of 1,1- dichloroethene . Toxicology and Applied Pharmacology 1995; 130: 48-56 .

52.

National Toxicology Programme . Carcinogenesis bioassay of zearalenone. (CAS 17924-92-4) in F344/N rats and B6C3F1 mice (feed study). NTP Technical report No TR 235. US DHSS, NIH 1982.

53.

Leskowiccz-Pfohl A , Ghedira-Chekir L , Bacha H. Genotoxicity of zearalenone, an estrogenic mycotoxin: DNA adduct formation in female mouse tissues . Carcinogenesis 1995; 16: 2315-2320 .

54.

National Toxicology Programme . Toxicology and Carcinogenesis studies of Benzaldehyde (CAS 100-52-7) in F344/N rats and B6C3F1 mice (gavage studies). NTP Technical report No TR 378. US DHSS, NIH 1990.

55.

Ashby JW , Paton D. Chemicals for evaluating the sensitivity and specificity of reduced transgenic rodent cancer bioassay protocols . Mutation Research 1995; 331: 27-38 .

56.

Tennant RW. Identifying carcinogens. A strategy for use of abbreviated models . Toxicologic Pathology 1997; 25: 240-241 .

57.

Ashby J. Alternatives to the 2-species bioassay for the identification of potential human carcinogens . Human and Experimental Toxicology 1996; 15: 183-202 .